Ani Pharmaceuticals (ANIP) Short term Debt (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 11 years of Short term Debt data on file, last reported at $19.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 72.41% year-over-year to $19.3 million; the trailing twelve-month figure through Mar 2026 stood at $19.3 million (up 72.41% YoY), and the FY2025 full-year result was $17.3 million, up 88.27% from the prior year.
• Short term Debt rose to $19.3 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $19.3 million in Q1 2026 to a low of $414000.0 in Q1 2024.
• A 5-year average of $5.8 million and a median of $850000.0 in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt slumped 94.66% in 2022 and surged 2603.62% in 2025, its largest moves.
• Tracing ANIP's Short term Debt over 5 years: stood at $850000.0 in 2022, then surged by 1343.06% to $12.3 million in 2023, then fell by 25.22% to $9.2 million in 2024, then jumped by 88.27% to $17.3 million in 2025, then gained by 11.76% to $19.3 million in 2026.
• Business Quant data shows ANIP's Short term Debt at $19.3 million in Q1 2026, $17.3 million in Q4 2025, and $15.2 million in Q3 2025.